Table 2.

Frequencies and associations of different venetoclax dose intensities and clinical outcomes

Dose intensity, %Frequency in unfit vs fit patients, %ORR, %CRR, %uMRD <10–4, %3-Year PFS from EOT, %3-Year OS from EOT, %
<80 vs ≥80 39.6 vs 17.6 83.3 vs 98.2 (P < .001) 46.7 vs 56.4 (P = .074) 74.2 vs 87.9 (P < .001) 82.8 vs 79.3 (HR,1.40; 95% CI, 0.91-2.15; P = .123) 94.1 vs 90.8 (HR, 1.41; 95% CI 0.69-2.88; P = .340) 
<70 vs ≥70 34.7 vs 12.5 81.0 vs 98.0 (P < .001) 46.0 vs 56.0 (P = .083) 70.0 vs 88.4 (P < .001) 76.1 vs 83.6 (HR, 1.66; 95% CI, 1.07-2.56; P = .022) 90.0 vs 94.2 (HR, 1.56; 95% CI, 0.77-3.21; P = .229) 
<60 vs ≥60 28.0 vs 8.0 75.3 vs 98.2 (P < .001) 44.2 vs 55.7 (P = .068) 63.6 vs 88.6 (P < .001) 73.1 vs 83.7 (HR, 1.80; 95% CI, 1.14-2.84; P = .011) 89.8 vs 93.9 (HR, 1.42; 95% CI, 0.65-3.10; P = .379) 
<50 vs ≥50 21.8 vs 5.1 70.7 vs 97.7 (P < .001) 43.1 vs 55.2 (P = .087) 58.6 vs 88.1 (P < .001) 69.2 vs 83.8 (HR, 2.25; 95% CI, 1.40-3.62; P < .001) 90.1 vs 93.7 (HR, 1.39; 95% CI, 0.59-3.26; P = .449) 
Dose intensity, %Frequency in unfit vs fit patients, %ORR, %CRR, %uMRD <10–4, %3-Year PFS from EOT, %3-Year OS from EOT, %
<80 vs ≥80 39.6 vs 17.6 83.3 vs 98.2 (P < .001) 46.7 vs 56.4 (P = .074) 74.2 vs 87.9 (P < .001) 82.8 vs 79.3 (HR,1.40; 95% CI, 0.91-2.15; P = .123) 94.1 vs 90.8 (HR, 1.41; 95% CI 0.69-2.88; P = .340) 
<70 vs ≥70 34.7 vs 12.5 81.0 vs 98.0 (P < .001) 46.0 vs 56.0 (P = .083) 70.0 vs 88.4 (P < .001) 76.1 vs 83.6 (HR, 1.66; 95% CI, 1.07-2.56; P = .022) 90.0 vs 94.2 (HR, 1.56; 95% CI, 0.77-3.21; P = .229) 
<60 vs ≥60 28.0 vs 8.0 75.3 vs 98.2 (P < .001) 44.2 vs 55.7 (P = .068) 63.6 vs 88.6 (P < .001) 73.1 vs 83.7 (HR, 1.80; 95% CI, 1.14-2.84; P = .011) 89.8 vs 93.9 (HR, 1.42; 95% CI, 0.65-3.10; P = .379) 
<50 vs ≥50 21.8 vs 5.1 70.7 vs 97.7 (P < .001) 43.1 vs 55.2 (P = .087) 58.6 vs 88.1 (P < .001) 69.2 vs 83.8 (HR, 2.25; 95% CI, 1.40-3.62; P < .001) 90.1 vs 93.7 (HR, 1.39; 95% CI, 0.59-3.26; P = .449) 

or Create an Account

Close Modal
Close Modal